Tomi Jun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tomi Jun has a total of 362 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Sacher
Princess Margaret Cancer Centre 7 Toronto, ON
18 shared publications - Jayesh Desai
Peter MacCallum Cancer Centre, Melbourne, Australia
18 shared publications - Jennifer L. Schutzman
26Oncology, Genentech, South San Francisco, California
18 shared publications - Julie Chang
Department of Bioengineering, Stanford University, Stanford, CA, USA
18 shared publications - Kenneth K. Yau
Hoffmann-La Roche Limited, Mississauga, Canada
18 shared publications - Neekesh V. Dharia
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
18 shared publications
Latest Publications
- Open Access
Bacteroidetes promote hepatocellular carcinoma progression and resistance to immunotherapy
Background and Aims: Growing evidence highlight the critical role of the gut microbiome in tumorigenesis and response to immunotherapies. However, the impact of gut microbes on hepatocellular carcinoma (HCC) progression and response to immune-checkpoint blockade (ICB) remains unclear due to the lack of combined preclinical and clinical studies. Approach & Results: We performed 16S rRNA of cross-cohort stool samples from 10 HCC responders (R) and 40 non-responders (NR) to ICB at baseline and on-treatment time-points. We identified an enrichment of Bacteroidetes in NR. To study the role of the microbiome in the cancer immune response, we generated an immunogenic mouse model of HCC via hydrodynamic tail-vein injection (HDTVI) of DNA plasmids mimicking common HCC alterations and immunogenicity by expressing model antigens (MYC-lucOS;CTNNB1 tumors). We found that antibiotic (ABX)-induced dysbiosis promoted a pro-tumorigenic effect in the MYC-lucOS;CTNNB1 HCC model by the expansion of a specific Bacteroidetes, Parabacteroides distasonis. Colonization of mice carrying MYC-lucOS;CTNNB1 HCCs with Parabacteroides distasonis confirmed its pro-tumorigenic effect in vivo. Furthermore, we explored the effects of colonizing with microbiotas from patients and showed that microbiota from a NR donor enriched in Bacteroidetes promoted faster tumorigenesis than microbiota from a R donor with reduced Bacteroidetes. We isolated 6 Bacteroidetes species from the NR donor, cultured them, and used them as a cocktail to colonize mice; similarly, mice transplanted with this cocktail showed increased tumorigenesis and reduced survival. Conclusions: This study identified Bacteroidetes enrichment as a potential biomarker of ICB resistance in HCC and, by using immunogenic mouse models, established that Bacteroidetes abundance influences tumor development.
Open AccessBacteroidetes promote hepatocellular carcinoma progression and resistance to immunotherapy
Background and Aims: Growing evidence highlight the critical role of the gut microbiome in tumorigenesis and response to immunotherapies. However, the impact of gut microbes on hepatocellular carcinoma (HCC) progression and response to immune-checkpoint blockade (ICB) remains unclear due to the lack of combined preclinical and clinical studies. Approach & Results: We performed 16S rRNA of cross-cohort stool samples from 10 HCC responders (R) and 40 non-responders (NR) to ICB at baseline and on-treatment time-points. We identified an enrichment of Bacteroidetes in NR. To study the role of the microbiome in the cancer immune response, we generated an immunogenic mouse model of HCC via hydrodynamic tail-vein injection (HDTVI) of DNA plasmids mimicking common HCC alterations and immunogenicity by expressing model antigens (MYC-lucOS;CTNNB1 tumors). We found that antibiotic (ABX)-induced dysbiosis promoted a pro-tumorigenic effect in the MYC-lucOS;CTNNB1 HCC model by the expansion of a specific Bacteroidetes, Parabacteroides distasonis. Colonization of mice carrying MYC-lucOS;CTNNB1 HCCs with Parabacteroides distasonis confirmed its pro-tumorigenic effect in vivo. Furthermore, we explored the effects of colonizing with microbiotas from patients and showed that microbiota from a NR donor enriched in Bacteroidetes promoted faster tumorigenesis than microbiota from a R donor with reduced Bacteroidetes. We isolated 6 Bacteroidetes species from the NR donor, cultured them, and used them as a cocktail to colonize mice; similarly, mice transplanted with this cocktail showed increased tumorigenesis and reduced survival. Conclusions: This study identified Bacteroidetes enrichment as a potential biomarker of ICB resistance in HCC and, by using immunogenic mouse models, established that Bacteroidetes abundance influences tumor development.
- Open Access
- 9 July 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (30) , JCO2500040-3253
Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
Divarasib (GDC-6036), an oral, highly potent and selective next-generation KRAS G12C inhibitor, has demonstrated a manageable safety profile and promising antitumor activity in patients with advanced KRAS G12C –positive non–small cell lung cancer (NSCLC). Here, we report long-term (≥1 year) follow-up of single-agent divarasib from the ongoing, open-label, and multicenter phase I study (ClinicalTrials.gov identifier: NCT04449874 ). The primary objective was safety, and the other objectives included preliminary antitumor activity. Overall, 65 patients with advanced KRAS G12C –positive NSCLC received single-agent oral divarasib 50-400 mg once daily and 31 patients (48%) were treated beyond 1 year. Divarasib continued to be well tolerated, and the safety profile beyond 1 year was consistent with the overall safety profile. In patients with measurable disease at baseline across all dose levels (n = 63), the confirmed objective response rate was 55.6% (95% CI, 42.5 to 68.1), and the median duration of response was 18.0 months (95% CI, 11.1 to 24.9). The median progression-free survival was 13.8 months (95% CI, 9.8 to 25.4) in the overall population (N = 65) and 15.3 months (95% CI, 12.3 to 26.1) among patients assigned to the 400-mg dose level (n = 44). With extended follow-up, divarasib demonstrated long-term safety and antitumor activity in patients with advanced KRAS G12C –positive NSCLC.
- 9 July 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (30) , JCO2500040-3253
Open AccessSingle-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
Divarasib (GDC-6036), an oral, highly potent and selective next-generation KRAS G12C inhibitor, has demonstrated a manageable safety profile and promising antitumor activity in patients with advanced KRAS G12C –positive non–small cell lung cancer (NSCLC). Here, we report long-term (≥1 year) follow-up of single-agent divarasib from the ongoing, open-label, and multicenter phase I study (ClinicalTrials.gov identifier: NCT04449874 ). The primary objective was safety, and the other objectives included preliminary antitumor activity. Overall, 65 patients with advanced KRAS G12C –positive NSCLC received single-agent oral divarasib 50-400 mg once daily and 31 patients (48%) were treated beyond 1 year. Divarasib continued to be well tolerated, and the safety profile beyond 1 year was consistent with the overall safety profile. In patients with measurable disease at baseline across all dose levels (n = 63), the confirmed objective response rate was 55.6% (95% CI, 42.5 to 68.1), and the median duration of response was 18.0 months (95% CI, 11.1 to 24.9). The median progression-free survival was 13.8 months (95% CI, 9.8 to 25.4) in the overall population (N = 65) and 15.3 months (95% CI, 12.3 to 26.1) among patients assigned to the 400-mg dose level (n = 44). With extended follow-up, divarasib demonstrated long-term safety and antitumor activity in patients with advanced KRAS G12C –positive NSCLC.
- Open Access
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2400227
Decoding Recurrence in Early-Stage and Locoregionally Advanced Non–Small Cell Lung Cancer: Insights From Electronic Health Records and Natural Language Processing
PURPOSE: Recurrences after curative resection in early-stage and locoregionally advanced non–small cell lung cancer (NSCLC) are common, necessitating a nuanced understanding of associated risk factors. This study aimed to establish a natural language processing (NLP) system to efficiently curate recurrence data in NSCLC and analyze risk factors longitudinally. PATIENTS AND METHODS: Electronic health records of 6,351 patients with NSCLC with >700,000 notes were obtained from Mount Sinai's data sets. A deep learning–based customized NLP system was developed to identify cohorts experiencing recurrence. Recurrence types and rates over time were stratified by various clinical features. Cohort description analysis, Kaplan-Meier analysis for overall recurrence-free survival (RFS) and distant metastasis-free survival (DMFS), and Cox proportional hazards analysis were performed. RESULTS: Of 1,295 patients with stage I–IIIA NSCLC with surgical resections, 336 patients (25.9%) experienced recurrence, as identified through NLP. The NLP system achieved a precision of 94.3%, a recall of 93%, and an F1 score of 93.5. Among 336 patients, 52.4% had local/regional recurrences, 44% distant metastases, and 3.6% unknown recurrence. RFS rates at years 1-5 were 93%, 81%, 73%, 67%, and 61%, respectively (96%, 89%, 84%, 80%, and 75% for distant metastasis). Stage-specific RFS rates at year 5 were 73% (IA), 62% (IB), 47% (IIA), 46% (IIB), and 20% (IIIA). Stage IB patients had a significantly higher likelihood of recurrence versus stage IA (adjusted hazard ratio [aHR], 1.63; P = .02). The RFS was lower in patients with clinically significant TP53 alteration ( v TP53 -negative or unknown significance), affecting overall RFS (aHR, 1.89; P = .007) and DMFS (aHR, 2.47; P = .009) among stage IA/IB patients. CONCLUSION: Our scalable NLP system enabled us to generate real-world insights into NSCLC recurrences, paving the way for predictive models for preventing, diagnosing, and treating NSCLC recurrence.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2400227
Open AccessDecoding Recurrence in Early-Stage and Locoregionally Advanced Non–Small Cell Lung Cancer: Insights From Electronic Health Records and Natural Language Processing
PURPOSE: Recurrences after curative resection in early-stage and locoregionally advanced non–small cell lung cancer (NSCLC) are common, necessitating a nuanced understanding of associated risk factors. This study aimed to establish a natural language processing (NLP) system to efficiently curate recurrence data in NSCLC and analyze risk factors longitudinally. PATIENTS AND METHODS: Electronic health records of 6,351 patients with NSCLC with >700,000 notes were obtained from Mount Sinai's data sets. A deep learning–based customized NLP system was developed to identify cohorts experiencing recurrence. Recurrence types and rates over time were stratified by various clinical features. Cohort description analysis, Kaplan-Meier analysis for overall recurrence-free survival (RFS) and distant metastasis-free survival (DMFS), and Cox proportional hazards analysis were performed. RESULTS: Of 1,295 patients with stage I–IIIA NSCLC with surgical resections, 336 patients (25.9%) experienced recurrence, as identified through NLP. The NLP system achieved a precision of 94.3%, a recall of 93%, and an F1 score of 93.5. Among 336 patients, 52.4% had local/regional recurrences, 44% distant metastases, and 3.6% unknown recurrence. RFS rates at years 1-5 were 93%, 81%, 73%, 67%, and 61%, respectively (96%, 89%, 84%, 80%, and 75% for distant metastasis). Stage-specific RFS rates at year 5 were 73% (IA), 62% (IB), 47% (IIA), 46% (IIB), and 20% (IIIA). Stage IB patients had a significantly higher likelihood of recurrence versus stage IA (adjusted hazard ratio [aHR], 1.63; P = .02). The RFS was lower in patients with clinically significant TP53 alteration ( v TP53 -negative or unknown significance), affecting overall RFS (aHR, 1.89; P = .007) and DMFS (aHR, 2.47; P = .009) among stage IA/IB patients. CONCLUSION: Our scalable NLP system enabled us to generate real-world insights into NSCLC recurrences, paving the way for predictive models for preventing, diagnosing, and treating NSCLC recurrence.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Representativeness of Study Participants
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Representativeness of Study Participants
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Purpose:To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a KRAS G12C mutation treated with single-agent divarasib (GDC-6036) in a phase 1 study.Experimental Design:Plasma samples were collected for serial ctDNA profiling at baseline (cycle 1 day 1 prior to treatment) and multiple on-treatment time points (cycle 1 day 15 and cycle 3 day 1).Results:KRAS G12C ctDNA was detectable from plasma samples in 72.9% (43/59) and 92.6% (50/54) of patients with non–small cell lung cancer and colorectal cancer, respectively, the majority of whom were eligible for study participation based on a local test detecting the KRAS G12C mutation in tumor tissue. Baseline ctDNA tumor fraction was associated with tumor type, disease burden, and metastatic sites. A decline in ctDNA level was observed as early as cycle 1 day 15. Serial assessment showed a decline in ctDNA tumor fraction associated with response and progression-free survival. Except for a few cases of KRAS G12C sub-clonality, on-treatment changes in KRAS G12C variant allele frequency mirrored changes in the overall ctDNA tumor fraction.Conclusions:Across tumor types, the KRAS G12C mutation likely represents a truncal mutation in the majority of patients. Rapid and deep decline in ctDNA tumor fraction was observed in patients responding to divarasib treatment. Early on-treatment dynamics of ctDNA were associated with patient outcomes and tumor response to divarasib treatment.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Purpose:To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a KRAS G12C mutation treated with single-agent divarasib (GDC-6036) in a phase 1 study.Experimental Design:Plasma samples were collected for serial ctDNA profiling at baseline (cycle 1 day 1 prior to treatment) and multiple on-treatment time points (cycle 1 day 15 and cycle 3 day 1).Results:KRAS G12C ctDNA was detectable from plasma samples in 72.9% (43/59) and 92.6% (50/54) of patients with non–small cell lung cancer and colorectal cancer, respectively, the majority of whom were eligible for study participation based on a local test detecting the KRAS G12C mutation in tumor tissue. Baseline ctDNA tumor fraction was associated with tumor type, disease burden, and metastatic sites. A decline in ctDNA level was observed as early as cycle 1 day 15. Serial assessment showed a decline in ctDNA tumor fraction associated with response and progression-free survival. Except for a few cases of KRAS G12C sub-clonality, on-treatment changes in KRAS G12C variant allele frequency mirrored changes in the overall ctDNA tumor fraction.Conclusions:Across tumor types, the KRAS G12C mutation likely represents a truncal mutation in the majority of patients. Rapid and deep decline in ctDNA tumor fraction was observed in patients responding to divarasib treatment. Early on-treatment dynamics of ctDNA were associated with patient outcomes and tumor response to divarasib treatment.